Grifols, S.A. $GRFS Shares Sold by Credit Industriel ET Commercial

Key Points

• Credit Industriel ET Commercial has reduced its stake in Grifols, S.A. by 21.5%, selling 99,100 shares during the second quarter, leaving it with 361,755 shares valued at approximately $3.27 million.
• Grifols received a downgrade from Wall Street Zen, moving from a "strong-buy" to a "buy" rating, while the consensus rating remains a "Moderate Buy" with a target price of $10.30.
• The company announced a special dividend of $0.1404 per share, which was paid out on August 20th, with a payout ratio of 11.97%.

Credit Industriel ET Commercial decreased its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 21.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 361,755 shares of the biotechnology company's stock after selling 99,100 shares during the quarter. Credit Industriel ET Commercial owned 0.05% of Grifols worth $3,270,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of GRFS. Ballentine Partners LLC acquired a new position in shares of Grifols during the 1st quarter worth about $77,000. Ascent Group LLC acquired a new position in shares of Grifols during the 2nd quarter worth about $141,000. Cerity Partners LLC raised its position in shares of Grifols by 22.8% during the 1st quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 4,129 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Grifols during the 1st quarter worth about $184,000. Finally, Sequoia Financial Advisors LLC raised its position in shares of Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares during the last quarter.

Wall Street Analysts Forecast Growth

GRFS has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Grifols from a "strong-buy" rating to a "buy" rating in a report on Saturday. Weiss Ratings reiterated a "hold (c)" rating on shares of Grifols in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Grifols in a report on Tuesday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th. Finally, Zacks Research upgraded shares of Grifols to a "hold" rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Grifols has a consensus rating of "Moderate Buy" and a consensus target price of $10.30.

Grifols Stock Performance

Shares of GRFS stock opened at $9.45 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. Grifols, S.A. has a 52 week low of $6.19 and a 52 week high of $11.14. The stock has a market capitalization of $6.50 billion, a PE ratio of 8.08, a P/E/G ratio of 0.32 and a beta of 0.69. The firm has a 50 day moving average of $10.00 and a two-hundred day moving average of $8.91.

Grifols Announces Dividend

The company also recently disclosed a special dividend, which was paid on Wednesday, August 20th. Stockholders of record on Tuesday, August 12th were given a dividend of $0.1404 per share. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's payout ratio is 11.97%.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.